Anne-Marie Frances
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Marie Frances has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alain Duvillard
Service ORL, Hôpital, Dijon, France
1 shared publication - Albert David
CHU Nantes, Service de Génétique Médicale Nantes France
1 shared publication - Aziz El-Amraoui
Institut Pasteur Institut De L'audition, AP‐HP, INSERM U1335, CNRS, Fondation Pour l'Audition, IHU reConnect, Progressive Sensory Disorders, Pathophysiology and Therapy Université Paris Cité Paris France
1 shared publication - Bettina Montaut-Verient
Service ORL, Maternité Régionale Adolphe-Pinard, Nancy, France
1 shared publication - Bruno Delobel
Cytogenetics Service, Saint Vincent de Paul Catholic Hospitals Association of Lille, Free Faculty of Medicine, Lille, France.
1 shared publication - Catherine Calais
Service ORL, CHU Hôtel Dieu, Nantes, France
1 shared publication
Latest Publications
- Open Access
- 11 May 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 1-19
Complete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis
Background: Usher syndrome (USH) combines sensorineural deafness with blindness. It is inherited in an autosomal recessive mode. Early diagnosis is critical for adapted educational and patient management choices, and for genetic counseling. To date, nine causative genes have been identified for the three clinical subtypes (USH1, USH2 and USH3). Current diagnostic strategies make use of a genotyping microarray that is based on the previously reported mutations. The purpose of this study was to design a more accurate molecular diagnosis tool. Methods: We sequenced the 366 coding exons and flanking regions of the nine known USH genes, in 54 USH patients (27 USH1, 21 USH2 and 6 USH3). Results: Biallelic mutations were detected in 39 patients (72%) and monoallelic mutations in an additional 10 patients (18.5%). In addition to biallelic mutations in one of the USH genes, presumably pathogenic mutations in another USH gene were detected in seven patients (13%), and another patient carried monoallelic mutations in three different USH genes. Notably, none of the USH3 patients carried detectable mutations in the only known USH3 gene, whereas they all carried mutations in USH2 genes. Most importantly, the currently used microarray would have detected only 30 of the 81 different mutations that we found, of which 39 (48%) were novel. Conclusions: Based on these results, complete exon sequencing of the currently known USH genes stands as a definite improvement for molecular diagnosis of this disease, which is of utmost importance in the perspective of gene therapy.
- 11 May 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 1-19
Open AccessComplete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis
Background: Usher syndrome (USH) combines sensorineural deafness with blindness. It is inherited in an autosomal recessive mode. Early diagnosis is critical for adapted educational and patient management choices, and for genetic counseling. To date, nine causative genes have been identified for the three clinical subtypes (USH1, USH2 and USH3). Current diagnostic strategies make use of a genotyping microarray that is based on the previously reported mutations. The purpose of this study was to design a more accurate molecular diagnosis tool. Methods: We sequenced the 366 coding exons and flanking regions of the nine known USH genes, in 54 USH patients (27 USH1, 21 USH2 and 6 USH3). Results: Biallelic mutations were detected in 39 patients (72%) and monoallelic mutations in an additional 10 patients (18.5%). In addition to biallelic mutations in one of the USH genes, presumably pathogenic mutations in another USH gene were detected in seven patients (13%), and another patient carried monoallelic mutations in three different USH genes. Notably, none of the USH3 patients carried detectable mutations in the only known USH3 gene, whereas they all carried mutations in USH2 genes. Most importantly, the currently used microarray would have detected only 30 of the 81 different mutations that we found, of which 39 (48%) were novel. Conclusions: Based on these results, complete exon sequencing of the currently known USH genes stands as a definite improvement for molecular diagnosis of this disease, which is of utmost importance in the perspective of gene therapy.